13F Holdings
中文EN

AARD Aardvark Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1774857 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.2%
TTM EPS YoY22.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-80.9%
ROA-73.5%
ROIC (approx.)-149.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets11.1%
Debt / equity0.00x
Current ratio9.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0—
R&D expense$48.94M$17.36M
SG&A expense$13.79M$5.30M
Operating income-$62.73M-$22.79M
Income tax$0$0
Net income-$57.59M-$20.59M
EBITDA-$62.69M-$22.77M
EPS (basic)-2.93-5.15
EPS (diluted)-2.93-5.15
Weighted avg. shares (diluted)19.62M4.00M
Balance sheet
Cash & equivalents$47.05M$61.64M
Short-term investments$62.98M$12.02M
Current assets$111.89M$74.14M
Total assets$117.18M$77.51M
Current liabilities$10.55M$4.93M
Total liabilities$10.55M$5.39M
Shareholders' equity$106.63M-$54.64M
Shares outstanding21.82M4.07M
Cash flow statement
Operating cash flow-$54.17M-$18.09M
Capital expenditure$95,000$109,000
Free cash flow-$54.27M-$18.20M
Investing cash flow-$49.67M-$12.00M
Financing cash flow$89.25M$81.99M
Depreciation & amortization$36,000$16,000
Stock-based compensation$3.95M$439,000

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.